These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 20354421)

  • 1. A favorable clinical trend is associated with CD8 T-cell immune responses to the human papillomavirus type 16 e6 antigens in women being studied for abnormal pap smear results.
    Nakagawa M; Gupta SK; Coleman HN; Sellers MA; Banken JA; Greenfield WW
    J Low Genit Tract Dis; 2010 Apr; 14(2):124-9. PubMed ID: 20354421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend.
    Kim KH; Greenfield WW; Cannon MJ; Coleman HN; Spencer HJ; Nakagawa M
    Cancer Immunol Immunother; 2012 Jan; 61(1):63-70. PubMed ID: 21842207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
    Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
    Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis.
    Wang-Johanning F; Lu DW; Wang Y; Johnson MR; Johanning GL
    Cancer; 2002 Apr; 94(8):2199-210. PubMed ID: 12001118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
    Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection of high-risk human papillomavirus (HPV) E6 and E7 oncogene transcripts increases the specificity of the detection of a cervical intraepithelial neoplasia (CIN)].
    Sotlar K; Diemer D; Stubner A; Menton S; Menton M; Dietz K; Wallwiener D; Bültmann B
    Verh Dtsch Ges Pathol; 2005; 89():195-200. PubMed ID: 18035691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
    Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
    Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions.
    Tong WW; Shepherd K; Garland S; Meagher A; Templeton DJ; Fairley CK; Jin F; Poynten IM; Zaunders J; Hillman RJ; Grulich AE; Kelleher AD; Carr A;
    J Infect Dis; 2015 Feb; 211(3):405-15. PubMed ID: 25139018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
    Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
    Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV-16-related proteins as the serologic markers in cervical neoplasia.
    Park JS; Park DC; Kim CJ; Ahn HK; Um SJ; Park SN; Kim SJ; Namkoong SE
    Gynecol Oncol; 1998 Apr; 69(1):47-55. PubMed ID: 9570998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses.
    Bourgault Villada I; Moyal Barracco M; Ziol M; Chaboissier A; Barget N; Berville S; Paniel B; Jullian E; Clerici T; Maillère B; Guillet JG
    Cancer Res; 2004 Dec; 64(23):8761-6. PubMed ID: 15574788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
    N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age.
    Molden T; Kraus I; Karlsen F; Skomedal H; Hagmar B
    Gynecol Oncol; 2006 Jan; 100(1):95-100. PubMed ID: 16153696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Investigation of E6/E7 mRNAs of high risk human papilloma virus types by a commercial automatized NASBA assay in cervical swabs].
    Ardiç N; Oztürk O; Ergünay K; Sezer O
    Mikrobiyol Bul; 2009 Jul; 43(3):463-9. PubMed ID: 19795622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predicting the persistence of genital human papillomavirus infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up.
    Branca M; Garbuglia AR; Benedetto A; Cappiello T; Leoncini L; Migliore G; Agarossi A; Syrjänen K;
    Int J STD AIDS; 2003 Jun; 14(6):417-25. PubMed ID: 12816671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
    de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
    Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer.
    de Vos van Steenwijk PJ; Heusinkveld M; Ramwadhdoebe TH; Löwik MJ; van der Hulst JM; Goedemans R; Piersma SJ; Kenter GG; van der Burg SH
    Cancer Res; 2010 Apr; 70(7):2707-17. PubMed ID: 20233872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
    Welters MJ; de Jong A; van den Eeden SJ; van der Hulst JM; Kwappenberg KM; Hassane S; Franken KL; Drijfhout JW; Fleuren GJ; Kenter G; Melief CJ; Offringa R; van der Burg SH
    Cancer Res; 2003 Feb; 63(3):636-41. PubMed ID: 12566307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.